Analgesic drug to prevent neuropathies induced by chemotherapies

PREVENTION OF NEUROPATHIC PAIN WITH EXPECTED REDUCED SIDE-EFFECT.

Chemotherapy-induced peripheral neuropathic pain is a major public health problem because available treatments produce incomplete relief, and have dose limiting side effects.

Our research team has developed a new asset that consists in :

1 | Repurposing of Riluzole, a non-selective TREK1 activator with known neuroprotective action initially prescribed in amyotrophic lateral sclerosis (ALS) as a solution to prevent and cure neuropathic pain induced by neurotoxic chemotherapies.

2 | Reduction of associated comorbidities

Competitive Advantages

● Response to unmet therapeutic need

● Attractive to speed up drug development

● Contribute to Health-Related Quality of Life improvement

● Non-opioid preventive pain relief

Development Status

● In vivo POC in oxaliplatin, taxane and vinca-alkalo.ds induced neuropathic mouse and rat models. Also, Riluzole didn’t affect the anticancer effect of oxaliplatinin the mouse model of colorectal cancer (ApcMin)

● Validation of a MoA based on TREK1 channel activation and inhibition of synaptic glutamate release without affecting the antineoplasic properties

● Ongoing Clinical Phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial on 210 patients with stage II/III colorectal cancer